SCHEMBL451140

SCHEMBL451140

CC(=O)C(C)(C)NCCONC(C)(C)C(C)=O

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8721527 0.86
SCHEMBL7127257 0.77 GAA (0.35) GAA
SCHEMBL25966308 0.75 ALDH1A1 (0.33) GAA
SCHEMBL5313149 0.75 POLB (0.32)
SCHEMBL455104 0.72 KDM4E (0.36) GAA
SCHEMBL1477727 0.72 KDM4E (0.42) GAA
SCHEMBL8475877 0.70 KDM4E (0.46)
SCHEMBL26452808 0.69 PAOX (0.37) GAA
SCHEMBL24779728 0.67 EPHX1 (0.41)
SCHEMBL14561907 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177326-A1 SELF-ASSEMBLING MOLECULES THAT ACCUMULATE IN ACIDIC TUMOR MICROENVIRONMENTS The Ohio State Innovation Foundation (US) 2017-06-14 EP claimed
WO-2016022987-A1 SELF-ASSEMBLING MOLECULES THAT ACCUMULATE IN ACIDIC TUMOR MICROENVIRONMENTS OHIO STATE INNOVATION FOUNDATION (US) 2016-02-11 WO claimed
US-20140363378-A1 SELF-ASSEMBLING MOLECULES THAT ACCUMULATE IN ACIDIC TUMOR MICROENVIRONMENTS THE OHIO STATE UNIVERSITY 2014-12-11 US claimed
WO-2013116645-A1 SELF-ASSEMBLING MOLECULES THAT ACCUMULATE IN ACIDIC TUMOR MICROENVIRONMENTS THE OHIO STATE UNIVERSITY (US) 2013-08-08 WO claimed
EP-0629617-B2 Heteroatom-bearing ligands and metal complexes thereof BRACCO INT BV (NL) 2007-09-26 EP claimed
CN-1055685-C Heteroatom-bearing ligands and metal complexes thereof BRAKER INTERNAT B V (NL) 2000-08-23 CN claimed
EP-0629617-B1 Heteroatom-bearing ligands and metal complexes thereof BRACCO INT BV (NL) 1998-04-29 EP claimed
US-5665329-A Heteroatom-bearing ligands and metal complexes thereof BRACCO INTERNATIONAL B.V. 1997-09-09 US claimed
CN-1099388-A Heteroatom-bearing ligands and metal complexes thereof BRISTOL MYERS SQIBB COMPANY (US) 1995-03-01 CN claimed
EP-0629617-A1 Heteroatom-bearing ligands and metal complexes thereof BRACCO International B.V. (NL) 1994-12-21 EP claimed
CN-111225679-B Novel peptide-based cancer imaging agents 俄亥俄州创新基金会 2024-03-29 CN disclosed
US-20230338584-A1 NOVEL PEPTIDE-BASED CANCER IMAGING AGENTS OHIO STATE INNOVATION FOUNDATION 2023-10-26 US disclosed
US-20220218834-A1 APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-07-14 US disclosed
US-11358982-B2 Methods for the iodination of biomolecules OHIO STATE INNOVATION FOUNDATION (US) 2022-06-14 US disclosed
WO-2020236952-A1 APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2020-11-26 WO disclosed
US-5656254-A Polyaza heteroatom-bearing ligands and metal complexes thereof for imaging or radiotherapy BRACCO INTERNATIONAL B.V. 1997-08-12 US disclosed
US-5627286-A Heteroatom-bearing ligands and metal complexes thereof BRACCO INTERNATIONAL B.V. 1997-05-06 US disclosed
US-5608110-A Heteroatom-bearing ligands and metal complexes thereof BRACCO INTERNATIONAL B.V. 1997-03-04 US disclosed
CN-1099388-A Heteroatom-bearing ligands and metal complexes thereof BRISTOL MYERS SQIBB COMPANY (US) 1995-03-01 CN disclosed
EP-0629617-A1 Heteroatom-bearing ligands and metal complexes thereof BRACCO International B.V. (NL) 1994-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140363378-A1 SELF-ASSEMBLING MOLECULES THAT ACCUMULATE IN ACIDIC TUMOR MICROENVIRONMENTS TP53, EGFR, HIF1A GAA 1018/4885
US-11358982-B2 Methods for the iodination of biomolecules TPO, LPO, MPO GAA 1752/4885
US-20220218834-A1 APOHEMOGLOBIN-HAPTOGLOBIN COMPLEXES AND METHODS OF USING THEREOF HBG1, HBG2, LPO GAA 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.